Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Data from Merck, Daiichi could support first approval for HER3 ADC

In BioCentury’s latest clinical report, Merck-Daiichi product scores on PFS after setback at FDA, plus updates from Ascendis, Boehringer, Atea and more

By Lauren Martz, Executive Director of Biopharma Intelligence, and Paul Bonanos, Director of Biopharma Intelligence
September 18, 2024 1:26 AM UTC

New progression-free survival results from the Phase III HERTHENA-Lung02 study add to the body of evidence that could support the first approval of patritumab deruxtecan (HER3-DXd).

The antibody-drug conjugate from Merck & Co. Inc. (NYSE:MRK) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) led to a significant improvement in progression-free survival (PFS) compared with chemotherapy, meeting the trial’s primary endpoint, among patients with EGFR-mutant non-small cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor treatment...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Ascendis Pharma A/S

Atea Pharmaceuticals Inc.

Biomarin Pharmaceutical Inc.

Boehringer Ingelheim GmbH

Daiichi Sankyo Co. Ltd.

Fulcrum Therapeutics Inc.

Merck & Co. Inc.